Effects of CD44 siRNA on inhibition, survival, and apoptosis of breast cancer cell lines (MDA-MB-231 and 4T1).

Background: Breast cancer (BC) is one of the most common cancers in the world. Despite the many advances that have been made in treating patients, many patients are still resistant to treatment. CD44 is one of the surface glycoproteins of BC cells that plays an important role in the proliferation of these cells and inhibition of their apoptosis.

CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer.

Breast cancer (BC) is one of the prevalent diseases and causes of death in women, and its incidence rate is increasing in numerous developed and developing countries. The common approach to BC therapy is surgery, followed by radiation therapy or chemotherapy, which doesn't lead to acceptable outcomes in many patients. Therefore, developing innovative strategies for treating BC is essential for the most effective therapy.

Comparative of Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line.

Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (EE), and drug loading (DL). DAPI staining and Flow cytometry techniques were employed to probe anticancer activities of the optimal formulations.